Envista (NYSE:NVST) Price Target Raised to $18.00 at Piper Sandler

Envista (NYSE:NVST) had its price objective raised by Piper Sandler from $17.00 to $18.00 in a research report sent to investors on Monday morning,Benzinga reports. Piper Sandler currently has a neutral rating on the stock.

Other equities research analysts have also issued research reports about the stock. Needham & Company LLC reissued a “hold” rating on shares of Envista in a research note on Thursday, October 31st. Robert W. Baird raised their target price on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Mizuho began coverage on Envista in a report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price target for the company. Jefferies Financial Group lifted their target price on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Finally, Wells Fargo & Company initiated coverage on Envista in a research report on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Envista currently has an average rating of “Hold” and an average target price of $20.21.

Envista Price Performance

Shares of NYSE NVST opened at $20.04 on Monday. Envista has a twelve month low of $15.15 and a twelve month high of $24.79. The company has a market capitalization of $3.45 billion, a price-to-earnings ratio of -2.58, a price-to-earnings-growth ratio of 1.82 and a beta of 1.33. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. The business has a 50 day simple moving average of $20.08 and a 200-day simple moving average of $19.04.

Institutional Investors Weigh In On Envista

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its holdings in Envista by 30.5% in the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after purchasing an additional 538 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of Envista by 50.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after buying an additional 728 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Envista by 69.7% in the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock worth $39,000 after buying an additional 804 shares during the last quarter. Huntington National Bank raised its holdings in shares of Envista by 97.8% in the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after purchasing an additional 949 shares during the period. Finally, Hudson Edge Investment Partners Inc. raised its holdings in shares of Envista by 4.8% in the 4th quarter. Hudson Edge Investment Partners Inc. now owns 24,931 shares of the company’s stock worth $481,000 after purchasing an additional 1,150 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.